ERBB2 and breast carcinoma: We, therefore, selected the SKBR3 mammary carcinoma cell line with an extra copy of ligand-independent Erbb-2 (Her2) and high endogenous expression of miR4673 (Fig. 1a) to study potential involvement of miR4673 in induction/suppression of non-encoded resistance mechanisms.